Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$2.0 billion.

  • Relay Therapeutics' Retained Earnings fell 1764.71% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 1764.71%. This contributed to the annual value of -$1.7 billion for FY2024, which is 2411.2% down from last year.
  • Latest data reveals that Relay Therapeutics reported Retained Earnings of -$2.0 billion as of Q3 2025, which was down 1764.71% from -$1.9 billion recorded in Q2 2025.
  • Relay Therapeutics' 5-year Retained Earnings high stood at -$446.4 million for Q1 2021, and its period low was -$2.0 billion during Q3 2025.
  • Its 5-year average for Retained Earnings is -$1.3 billion, with a median of -$1.3 billion in 2023.
  • In the last 5 years, Relay Therapeutics' Retained Earnings crashed by 16538.04% in 2021 and then crashed by 1764.71% in 2025.
  • Over the past 5 years, Relay Therapeutics' Retained Earnings (Quarter) stood at -$768.1 million in 2021, then plummeted by 37.82% to -$1.1 billion in 2022, then tumbled by 32.3% to -$1.4 billion in 2023, then dropped by 24.11% to -$1.7 billion in 2024, then dropped by 15.06% to -$2.0 billion in 2025.
  • Its Retained Earnings was -$2.0 billion in Q3 2025, compared to -$1.9 billion in Q2 2025 and -$1.8 billion in Q1 2025.